89bio Inc. (ETNB) PT Lowered to $12 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
89bio, Inc. (ETNB) Tops Q2 EPS by 8c
August 5, 2024 5:38 PM EDT89bio, Inc. (NASDAQ: ETNB) reported Q2 EPS of ($0.48), $0.08 better than the analyst estimate of ($0.56).
For earnings history and earnings-related data on 89bio, Inc. (ETNB) click here.
... More89bio Inc. (ETNB) Appoints Charles McWherter to its Board
August 5, 2024 8:04 AM EDT89bio, Inc. (Nasdaq: ETNB) today announced the appointment of Dr. Charles McWherter to its Board of Directors, effective July 30, 2024. Dr. McWherter most recently served as Chief Scientific Officer and President of Research and Development of CymaBay Therapeutics until it was acquired by Gilead Sciences in March 2024.
We are thrilled to welcome Charles, an esteemed industry leader, to our Board of Directors, said Rohan Palekar, CEO of 89bio. His expertise in drug development and profound knowledge of liver inflammation and fibrosis will be highly valuable as we advance our Phase 3 trials for non-cirrhotic and... More
